Analysts have been eager to weigh in on the Healthcare sector with new ratings on Zynex (ZYXI), Masimo (MASI) and Blueprint Medicines (BPMC).
Zynex (ZYXI)
In a report released today, James Terwilliger from Northland Securities reiterated a Buy rating on Zynex, with a price target of $16.50. The company’s shares closed last Tuesday at $15.54, close to its 52-week high of $16.96.
Terwilliger has an average return of 42.3% when recommending Zynex.
According to TipRanks.com, Terwilliger is ranked #1118 out of 6525 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zynex with a $16.67 average price target.
See today’s analyst top recommended stocks >>
Masimo (MASI)
In a report released today, Michael Matson from Needham maintained a Hold rating on Masimo. The company’s shares closed last Tuesday at $212.56, close to its 52-week high of $221.14.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 5.8% and a 56.7% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.
Currently, the analyst consensus on Masimo is a Moderate Buy with an average price target of $197.75, which is a -9.4% downside from current levels. In a report released yesterday, BTIG also maintained a Hold rating on the stock.
Blueprint Medicines (BPMC)
In a report released today, Andrew Berens from Leerink Partners maintained a Buy rating on Blueprint Medicines, with a price target of $105.00. The company’s shares closed last Tuesday at $58.63.
According to TipRanks.com, Berens is a 5-star analyst with an average return of 9.8% and a 63.6% success rate. Berens covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Seattle Genetics, and Clovis Oncology.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Blueprint Medicines with a $99.20 average price target, implying a 62.6% upside from current levels. In a report released yesterday, Raymond James also maintained a Buy rating on the stock with a $95.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.